Bio Pharma Dive
JUNE 24, 2025
New study results position Nuvalent to bring forward what it claims is a differentiated treatment for ROS1-positive lung cancer, a crowded indication with uncertain sales potential.
Scienmag
JUNE 23, 2025
A groundbreaking development in the early detection of hepatocellular carcinoma (HCC) has emerged from the halls of Wuhan Union Hospital at Huazhong University of Science and Technology. Researchers have unveiled a novel molecular imaging agent, designated 68 Ga-aGPC3-scFv or XH06, capable of precisely targeting glypican-3 (GPC3), a cell surface receptor that is prevalently overexpressed in HCC tumors.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Medical Xpress
JUNE 23, 2025
A new cancer treatment that delivers radiation directly to tumors by targeting two key markers simultaneously has been shown to be safe and effective in human trials. Acting like a "smart missile," the dual-targeting radiopharmaceutical is designed to attach to two vulnerable sites on cancer cells, enabling more precise and potent therapy. Early results show that nearly 90% of patients experienced either tumor shrinkage or disease stabilization.
World of DTC Marketing
JUNE 27, 2025
Physicians’ engagement with clinical trial data about potential new drugs varies significantly based on factors such as their specialty, practice setting, interest, and time constraints. Some specialists do want updates, but they want data, not sales information slanted to the potential label. 1. Specialists vs. General Practitioners : Specialists (e.g., oncologists, neurologists, cardiologists) typically follow clinical trials closely because their practice heavily depends on emerging tr
Speaker: Brian Richardson, Brian Richardson, Founder and CEO of Richardson Consulting Group
Let’s face it—most ethics and compliance training programs aren’t winning awards for engagement. But that doesn’t mean they can’t be effective, captivating, and maybe even enjoyable! Join learning design expert Brian Richardson for a dynamic session on how to breathe new life into your ethics and compliance training. We'll explore innovative strategies to bring traditionally dry topics to life, making them resonate with learners and drive tangible change.
The Pharma Data
JUNE 27, 2025
WHO Issues Global Safety Alert Over Vision Loss Risk Linked to Semaglutide-Based Medications The World Health Organization (WHO) has issued a global safety communication directed at healthcare professionals and regulatory authorities, warning of a potential but serious adverse effect associated with a class of widely used medications containing the active ingredient semaglutide.
Scienmag
JUNE 23, 2025
A groundbreaking development in neurosurgery has emerged with the FDA’s investment in an innovative AI-based technology designed to enhance the precision of brain mapping. At the forefront of this advancement is the Cirrus Resting State fMRI Software, a remarkable tool developed by a team of researchers at Washington University School of Medicine in St.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharmaceutical Technology
JUNE 26, 2025
Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh
The Pharma Data
JUNE 25, 2025
FDA Approves Label Update for Lilly’s Amyvid, Expanding Its Role in Alzheimer’s Disease Diagnosis and Therapy Guidance In a major development for Alzheimer’s diagnostics, Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved a revised label for Amyvid® (florbetapir F 18 injection) , an imaging agent used for detecting amyloid plaque density in the brains of patients undergoing evaluation for Alzheimer’s disease and other cognitive impairments.
Scienmag
JUNE 23, 2025
Hepatocellular carcinoma (HCC) is one of the most formidable challenges in oncology today. Representing the predominant form of liver cancer and ranking as the third-leading cause of cancer-related mortality worldwide, HCC’s aggressive nature and resistance to conventional therapies have long stymied clinicians and researchers alike. Yet, recent groundbreaking work at the VCU Massey Comprehensive Cancer Center, led by Dr.
pharmaphorum
JUNE 24, 2025
Skip to main content Tuesday 24 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Oncology -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -Wh
Advertisement
Enhancing Transparency & Efficiency Throughout the Trial Lifecycle for AI Readiness
Rethinking Clinical Trials
JUNE 26, 2025
In a new episode of the Rethinking Clinical Trials Podcast, Rich Platt, Hayden Bosworth, and Greg Simon of the NIH Pragmatic Trials Collaboratory discuss their JAMA Viewpoint, “Making Pragmatic Clinical Trials More Pragmatic.” Listen and subscribe to the podcast on SoundCloud or Apple Podcasts. In the Viewpoint, the authors propose solutions to the discordance between the results of pragmatic trials and the implementation of those results in healthcare settings. “I think one of the prob
The Pharma Data
JUNE 26, 2025
FDA Approves Streamlined Monitoring Requirements and REMS Program Removal for Bristol Myers Squibb’s CAR T Cell Therapies Breyanzi and Abecma, Marking Milestone Toward Expanding Access to Cancer Treatment In a significant regulatory development, Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has approved critical label updates for its two chimeric antigen receptor (CAR) T cell therapies— Breyanzi® (lisocabtagene maraleucel; liso-cel) and Abecma® (idecabtage
Scienmag
JUNE 24, 2025
A groundbreaking new analysis has unveiled a critical, yet often overlooked, aspect of postpartum health, emphasizing that severe bleeding after childbirth—known as postpartum hemorrhage (PPH)—may carry profound and long-lasting implications for women’s cardiovascular health. Drawing upon an immense dataset encompassing more than 9.7 million women from across Europe, North America, and Asia, this comprehensive review offers compelling evidence that the impact of PPH resonates far beyond th
Medical Xpress
JUNE 23, 2025
A newly developed PET radiotracer has shown the ability to produce high-quality images of real-time brain inflammation, according to research presented at the Society of Nuclear Medicine and Molecular Imaging 2025 Annual Meeting and published as a supplement in the Journal of Nuclear Medicine.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
World of DTC Marketing
JUNE 26, 2025
In biotech and pharma, a strong Vice President (VP) of Medical Affairs can significantly impact a company’s path to clinical success and market credibility. This isn’t a figurehead position—it’s a linchpin role that bridges science, strategy, and storytelling. But what exactly makes a VP of Medical Affairs truly effective in this high-stakes space? Here’s a breakdown of the key traits, capabilities, and mindsets that set the best apart from the rest. 1.
The Pharma Data
JUNE 24, 2025
Bio-Techne and USP Forge Strategic Alliance to Advance Quality Standards in Monoclonal Antibody and Gene Therapy Development Bio-Techne Corporation, a global life sciences company renowned for its high-performance reagents, instruments, and services, today announced a new distribution agreement with the United States Pharmacopeia (USP), a scientific nonprofit organization that sets public standards for the identity, strength, quality, and purity of medicines and biologics.
Scienmag
JUNE 21, 2025
In a groundbreaking new study published in the journal Schizophrenia (2025), researchers have unveiled compelling evidence of cell-type specific gene expression reductions in the interneurons of the cingulate gyrus in individuals diagnosed with schizophrenia and bipolar disorder. This discovery not only advances our understanding of the intricate cellular and molecular alterations underlying these complex psychiatric illnesses but also opens new avenues for targeted therapeutic intervention.
Medical Xpress
JUNE 23, 2025
Endoscopies could be replaced by far less invasive capsule sponge tests for half of all patients with Barrett's esophagus, a known precursor to esophageal cancer, according to a new study by researchers at the University of Cambridge, Addenbrooke's Hospital and Queen Mary University of London. The research was published in The Lancet.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Rethinking Clinical Trials
JUNE 23, 2025
A new section of the Living Textbook of Pragmatic Clinical Trials describes considerations for choosing patient-reported outcome measures in pragmatic clinical trials. “Where possible, investigators are encouraged to use measures with adequate support for validity that are in the public domain,” the authors wrote. The authors provide a set of questions to guide investigators in choosing approrpriate measures.
The Pharma Data
JUNE 22, 2025
Roche Unveils Promising Phase I/II Data for Next-Generation Bispecific Antibody NXT007 in Hemophilia A, Signaling a Major Step Toward Phase III Development Roche has shared encouraging new data from its early-stage clinical development program evaluating NXT007, a next-generation investigational bispecific antibody designed for people living with hemophilia A.
Scienmag
JUNE 27, 2025
In the intricate world of molecular biology, water has long been recognized as a fundamental player influencing the structure and function of proteins — the workhorse molecules of the cell. Despite its crucial role, the behavior and positioning of water molecules within protein environments have remained largely elusive to researchers, especially in the context of drug discovery.
Medical Xpress
JUNE 23, 2025
Published in The Journal of Infectious Diseases, a University of Minnesota research team has demonstrated that measuring SARS-CoV-2 in wastewater continues to accurately predict COVID-19 infections in a community.
Speaker: Amie Phillips Pablo, VP, Corporate Compliance & Privacy Officer at Novo Nordisk
In today’s complex healthcare environment, navigating third-party relationships has become even more challenging—whether it’s vendor relationships, employee activities, or patient-facing interactions. Left unmanaged, these conflicts can compromise trust, regulatory compliance, and even organizational reputation. So, how can healthcare teams stay ahead?
JAMA Internal Medicine
JUNE 22, 2025
This systematic review and meta-analysis examines the association of an early invasive strategy vs a conservative strategy with clinical outcomes for patients 70 years or older who present with acute coronary syndrome.
The Pharma Data
JUNE 25, 2025
Novartis Finalizes Acquisition of Regulus Therapeutics, Strengthening Its Renal Disease Portfolio with Promising ADPKD Therapy Novartis AG, a leading global pharmaceutical company, has officially completed its acquisition of Regulus Therapeutics Inc. , a biotechnology firm known for its expertise in microRNA-targeting therapies. The deal marks a significant step in Novartis’ strategic expansion into kidney disease therapeutics, particularly for autosomal dominant polycystic kidney disease (ADPKD
Scienmag
JUNE 27, 2025
In recent years, the relationship between the human microbiota and cancer treatment outcomes has emerged as one of the most compelling frontiers in medical research. These intricate microbial ecosystems dwelling within our intestines exert profound influences on how patients respond to therapy, how side effects manifest, and ultimately on survival rates.
XTalks
JUNE 25, 2025
Gilead Sciences has announced the highly awaited FDA approval of its HIV treatment Yeztugo (lenacapavir). The therapy is the first and only long-acting injectable for HIV pre-exposure prophylaxis (PrEP) that provides protection for six months with a single dose, meaning it only has to be taken twice a year. The approval marks a significant step forward in HIV prevention, offering a convenient alternative to daily oral PrEP regimens and monthly or bi-monthly injectable options.
Advertisement
Download this comprehensive guide to AI and ML in the R&D Laboratory Setting.
STAT News
JUNE 27, 2025
The Supreme Court on Friday upheld a key Affordable Care Act provision requiring health insurers to cover certain recommended preventive services cost-free. The decision delivers a victory to health advocates, because services including cancer screenings, statins, and HIV prevention drugs called PrEP will continue to be available at no cost to many Americans.
The Pharma Data
JUNE 27, 2025
UCB Announces Promising Phase 3 Results for Fenfluramine in CDKL5 Deficiency Disorder, Marking a Major Step Forward in Rare Epilepsy Treatment UCB , a global biopharmaceutical company committed to developing innovative therapies for neurological and immunological conditions, has announced positive top-line results from its Phase 3 GEMZ study evaluating fenfluramine as an adjunctive treatment for seizures associated with CDKL5 Deficiency Disorder (CDD).
Scienmag
JUNE 26, 2025
A groundbreaking new book authored by an international team of researchers reveals the transformative potential of data-driven decision-making in healthcare, promising to save lives and significantly reduce treatment times. The book, titled Analytics Edge in Healthcare , serves as an indispensable resource tailored for health professionals, policymakers, and decision-makers eager to harness the power of advanced analytics in clinical and operational settings.
XTalks
JUNE 25, 2025
Caris Life Sciences has officially stepped onto the public stage with its initial public offering (IPO), pricing 23,529,412 shares of its common stock at $21.00 per share. The IPO, which launched on June 18, 2025, on the Nasdaq Global Select Market under the ticker “CAI,” raised approximately $494 million before expenses. The offering drew attention from institutional investors, including Neuberger Berman, which indicated plans to purchase up to $75 million in shares.
Expert insights. Personalized for you.
283 
Let's personalize your content